Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 66, Issue -, Pages 65-69Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/ard.2007.078493
Keywords
-
Categories
Funding
- NIAID NIH HHS [R01 AI042269, R01 AI049954, R01AI49954, R01AI068787, R01AI42269, R01 AI068787] Funding Source: Medline
Ask authors/readers for more resources
T cells from patients with systemic lupus erythematosus exhibit a notable array of defects that probably contribute to the origin and development of the disease. Such abnormalities include an abnormal response to stimulation, aberrant expression of molecules that play key roles in intracellular signalling pathways, altered transcription factor activation and binding, and skewed gene expression. The combination of these alterations leads the cell to the expression of a particular phenotype that intense research has gradually uncovered over the last years. The aim of this article is to review the findings that have allowed us to better understand the behaviour of the lupus T cell and highlight the molecules that represent potential therapeutic targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available